medigraphic.com

2019, Number 1

<< Back Next >>

Rev Clin Esc Med 2019; 9 (1)

Cardiomiopatía diabética: entidad poco conocida y el impacto terapéutico de los inhibidores del cotransporrtador sodio-glucosa tipo 2 en el miocardio diabetico

Navarro SJ, Vinocour FM

Language: Spanish
References: 45
Page: 11-27
PDF size: 409.42 Kb.


ABSTRACT

Diabetic cardiomyopathy is an entity that originates from a microvascular complication of diabetes mellitus type 2, which develops by the synergy of several metabolic elements generated by chronic hyperglycemia and oxidation of free fatty acids that cause a harmful impact by different biochemical pathways at the level of the myocardium causing structural and functional changes, as a consequence they generate diastolic and early systolic dysfunction before producing associated symptoms. Due to the above it is very important to understand this pathology from the physiopathological level, on the other hand, to establish an opportune diagnosis by established methods such as echocardiography and possible treatments at present for the improvement of myocardial contractility. In the present article we review the physiopathological mechanisms based on the metabolic processes in diabetes mellitus that affect the myocardium, generating a decrease in cardiac efficiency, thus causing a long-term heart failure, and also analyzing the most precise and conclusive diagnostic methods. to establish diabetic cardiomyopathy. On the other hand, the therapeutic effects of the inhibitory drugs of the sodium-glucose cotransporter type 2 in the myocardium will be analyzed on the basis of their benefits already proven benefits and in theories and hypotheses that have been raised from experimental and observational investigations.


REFERENCES

  1. Acar E, Ural D, Bildirici U, Şahin T, Yılmaz I. Diabetic cardiomyopathy. Anadolu Kardiyol Derg 2011; 11: 732-7.

  2. Aneja A, Tang WH, Bansilal S, Garcia M. Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. Am J Med. 2008; 121:748-57.

  3. Brahma M, Pepin M, Wende A. My Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy. Diabetes Metab J. 2017; 41: 1–9.

  4. Niemann B, Rohrbach S, Miller MR, Newby DE, Fuster V, Kovacic JC. Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution Part 3 of a 3-Part Series. J Am Coll Cardiol 2017; 70:230–51.

  5. Paneni F, Beckman J, Creager M. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013; 34:2436-43.

  6. Jia G, Whaley-Connell A, Sowers A. Diabetic cardiomyopathy: a hyperglycaemia and insulin-resistanceinduced heart disease. Diabetologia. 2018; 61:21-28.

  7. Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy An Update of Mechanims Contributing to This Clinical Entity. Circ Res. 2018; 122:624-638.

  8. Shah M, Brownlee M. Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. Circ Res. 2016; 118:1808-29.

  9. Gilca GE, Stefanescu G, Badulescu O, Tanase DM, Bararu I, Ciocoiu M. Diabetic Cardiomyopathy: Current Approach and Potential Diagnostic and therapeutic Targets. J Diabetes Res. 2017; 2017:1310265.

  10. Wang C, Hess C, Hiatt W, Goldfine A. Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations. Circulation. 2016; 133:2459–2502.

  11. Hu X, Bai T, Xu Z, Liu Q, Zheng Y, Cai L. Pathophysiological Fundamentals of Diabetic Cardiomyopathy. Compr Physiol. 2017; 7:693-711.

  12. Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage. J Diabetes Invest 2014; 5: 623–634.

  13. Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther. 2018; 8:47-56.

  14. Kovács A, Oláh A, Lux A, et al. Strain and strain rate by speckle-tracking echocardiography correlate with pressure-volume loop-derived contractility indices in a rat model of athlete’s heart. Am J Physiol Heart Circ Physiol. 2015; 308:H743-8.

  15. Loncarevic B, Trifunovic D, Soldatovic I, Vujisic- Tesic B. Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. BMC Cardiovasc Disord. 2016; 16:242.

  16. Yang H, Wang Y, Negishi K, Nolan M, Marwick T. Pathophysiological effects of different risk factors for heart failure. Open Heart. 2016; 3(1): e000339.

  17. Aronsen JM, Swift F, Sejersted OM. Cardiac sodium transport and excitation–contraction coupling. J Mol Cell Cardiol. 2013; 61:11-9.

  18. Despa S, Bers D. Na+ transport in the normal and failing heart — Remember the balance. J Mol Cell Cardiol. 2013; 61:2-10.

  19. Lambert R, Srodulski S, Peng X, Margulies K, Despa F, Despa S. Intracellular Na+ Concentration ([Na+] i) Is Elevated in Diabetic Hearts Due to Enhanced Na+–Glucose Cotransport. J Am Heart Assoc. 2015; 4(9): e002183.

  20. Bertero E, Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium Hypothesis. Cardiovasc Res. 2018; 114:12-18.

  21. Zinman B, Wanner C, Lachin J, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117-28.

  22. Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:644-657.

  23. Cefalu W, Bakris G, Blonde L, et al. Standards of Medical Care in Diabetes. Diabetes Care. 2017; 40: S4-S5.

  24. Hattersley A, Thorens B. Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion. N Engl J Med. 2015; 373:974-6.

  25. Staels B. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. Am J Med. 2017; 130: S30-S39.

  26. Marx N, McGuire D. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016; 37:3192-3200.

  27. Heerspink H, Perkins B, Fitchett D, Husain M, Cherney D. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.Circulation. 2016; 134:752-72.

  28. Taylor S, Blau J, Rother K. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015; 100:2849-52.

  29. Packer M, Anker S, Butler J, Filippatos G, Zannad F. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of PatientsWith Heart Failure Proposal of a Novel Mechanism of Action. JAMA Cardiol. 2017; 2:1025-1029.

  30. Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2- inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018; 17:5.

  31. Baker WL, Buckley LF, Kelly MS, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017; 6: e005686.

  32. Kimura G. Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure. Circ J. 2016; 80:2277-2281.

  33. McMurray J. EMPA-REG: the “diuretic hypothesis.” J Diabetes Complications 2016; 30:3–4.

  34. Kaplan A, Abidi E, El-Yazbi A, Eid A, Booz GW, Zouein FA. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail Rev. 2018 May;23(3):419-437.

  35. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo R. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care 2016; 39:717–725.

  36. Lee TM, Changd NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017; 104:298-310.

  37. Lopaschuk G, Verma S. Empagliflozin’s Fuel Hypothesis: Not so Soon. Cell Metab. 2016; 24:200-2.

  38. Mudaliar S, Alloju S, Henry R. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care 2016; 39:1115– 1122.

  39. Heart Relies on Ketone Bodies as a Fuel. Circulation. 2016; 133:698-705.

  40. Baartscheer A, Schumacher C, Wüst R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia (2017) 60:568–573.

  41. Bertero E, Roma LP, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018; 114:12-18.

  42. Packer M. Role of the Sodium-Hydrogen Exchanger in Mediating the Renal Effects of Drugs Commonly Used in the Treatment of Type 2 Diabetes. Diabetes Obes Metab. 2018; 20:800-811.

  43. Packer M. Activation and Inhibition of Sodium- Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure. Circulation. 2017; 136:1548–1559.

  44. Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2017; 61:722-726.

  45. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REGOUTCOME Trial: A "Thrifty Substrate Hypothesis. Diabetes Care 2016; 39:1108–111.




2020     |     www.medigraphic.com